FLT3 and acute myeloid leukemia: Gilteritinib is a molecule whose efficacy was evaluated in a randomized, open-label phase 3 clinical trial conducted in adult patients with relapsed or refractory AML with FLT3 gene mutation (ADMIRAL study).